---
title: "HUTCHMED (China): Oncology sales surged over 40% in China, global launches expanded, and cash reserves remained strong"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294357093.md"
description: "Strong China oncology sales and global launches drove 23% growth in marketed product revenue, while net income normalized after a prior-year divestment gain. R&D investment accelerated, and the company maintained a robust $1.37 billion cash position.Original document: HUTCHMED (China) Limited [13] Interim report — Jul. 30 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-30T11:34:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294357093.md)
  - [en](https://longbridge.com/en/news/294357093.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294357093.md)
---

# HUTCHMED (China): Oncology sales surged over 40% in China, global launches expanded, and cash reserves remained strong

Strong China oncology sales and global launches drove 23% growth in marketed product revenue, while net income normalized after a prior-year divestment gain. R&D investment accelerated, and the company maintained a robust $1.37 billion cash position.

Original document: HUTCHMED (China) Limited \[13\] Interim report — Jul. 30 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [HCM.US](https://longbridge.com/en/quote/HCM.US.md)
- [00013.HK](https://longbridge.com/en/quote/00013.HK.md)

## Related News & Research

- [Veyberg Test Announces Expanded Global Market Research and Investment Analysis Strategy](https://longbridge.com/en/news/296212481.md)
- [Elicera corrects CARMA update, says 2 of 3 prior CAR T patients show tumor response, not all 3](https://longbridge.com/en/news/295928409.md)
- [How Hong Kong infrastructure, AI firms are tapping Malaysia’s growth prospects](https://longbridge.com/en/news/296165689.md)
- [TriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth Conference](https://longbridge.com/en/news/296174254.md)
- [IPH: Three late-stage oncology assets drive value, with major partnerships and pivotal data due in H2 2026](https://longbridge.com/en/news/295950027.md)